Article

(2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterole-mia: Recent and Emerging Therapeutic Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets. pp. 1018-1028.

(2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. Endocrine Metabolic & Immune Disorders-Drug Targets. pp. 1018-1028. ISSN 1871-5303

(2022) Effect of diabetes on efferocytosis process. Molecular Biology Reports. pp. 10849-10863.

(2022) Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update. Biochemical Genetics. pp. 453-481. ISSN 0006-2928

(2022) The role of efferocytosis in neuro-degenerative diseases. Neurological Sciences. pp. 1593-1603. ISSN 1590-1874

(2021) LncRNAs as putative biomarkers and therapeutic targets for Parkinson's disease. Neurological Sciences. pp. 4007-4015.

(2020) Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches. Current gene therapy. pp. 386-394. ISSN 1566-5232

(2019) Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular Neurobiology. pp. 4799-4811. ISSN 0893-7648

(2019) Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review. Journal of cellular biochemistry. pp. 8891-8898. ISSN 0730-2312

(2019) Roles of E6 and E7 Human Papillomavirus Proteins in Molecular Pathogenesis of Cervical Cancer. Current protein & peptide science. pp. 926-934. ISSN 1389-2037